Delivery Order SPE2DB25D3012-SPE2DB25FWWMM

Award Date 3/28/25
Potential Completion Date 3/31/25
Potential Value $2.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REMIFENTANIL 1 MG VIALS, a specialty medication, with a ceiling value of $2,270.35 and a completion date of April 3, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,816.30 delivery order is for the supply of REMIFENTANIL 2 MG VIALS, a specialty medication, to support military healthcare programs. The contract has a firm fixed price and an ultimate completion date of March 25, 2025. This award is associated with Amerisourcebergen's $999,999,999 Indefinite Delivery Contract...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,200.38, is for the delivery of REMIFENTANIL 1 MG VIALS, a specialty medication. The contract is a Firm Fixed Price Delivery Order, with a completion date of January 14, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,380.66, is a Delivery Order under the Defense Logistics Agency (DLA) Troop Support Medical's Indefinite Delivery Contract (IDC) valued at $999,999,999. The contract is for the delivery of REMIFENTANIL 1 MG VIALS to support military healthcare programs. The award has no set-aside designation, indicating open competition....
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order valued at $1,063.41 for the supply of REMIFENTANIL 1 MG VIALS. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of October 22, 2024. The contract is a Firm Fixed Price arrangement, and no set-aside designation was used. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,917.75, is for the delivery of REMIFENTANIL 2 MG VIALS, a specialty medication. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is March 5, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $11,001.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which has a completion date of December 31, 2024, is for the delivery of REMIFENTANIL 1 MG VIALS, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, and there is no set-aside designation. Amerisourcebergen holds a significant Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,731.19 Firm Fixed Price delivery order contract is for the supply of REMIFENTANIL 2 MG VIALS, a specialty medication. The contract has an ultimate completion date of April 3, 2025 and is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen holds a $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,236.17, is for the delivery of REMIFENTANIL 1 MG VIALS, a specialty medication. This contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. The IDC serves as...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,852.40, is for the delivery of REMIFENTANIL 2 MG VIALS, a pharmaceutical product. The contract is a firm fixed-price delivery order with a completion date of May 13, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB25D3012
    Indefinite Delivery Contract
  • SPE2DB25D3012-SPE2DB25FWWMM
    Delivery Order

This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of REMIFENTANIL 1 MG VIALS. The contract is a Delivery Order with a Firm Fixed Price of $2,270.35 and a completion date of March 31, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 6/27/25, 12:17 PM